Article
A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.
Molecular cancer therapeutics - 1 Oct 2021
DaSilva John O, Yang Katie, Surriga Oliver, Nittoli Thomas, Kunz Arthur, Franklin Matthew C, Delfino Frank J, Mao Shu, Zhao Feng, Giurleo Jason T, Kelly Marcus P, Makonnen Sosina, Hickey Carlos, Krueger Pamela, Foster Randi, Chen Zhaoyuan, Retter Marc W, Slim Rabih, Young Tara M, Olson William C, Thurston Gavin, Daly Christopher
Abstract excerpt
Lung cancers harboring mesenchymal-to-epithelial transition factor (MET) genetic alterations, such as exon 14 skipping mutations or high-level gene amplification, respond well to MET-selective tyrosine kinase inhibitors (TKI). However, these agents benefit a relatively small group of patients (4%-5% of lung cancers), and acquired resistance limits response durability. An antibody-drug conjugate (ADC) targeting...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.